JohnsonJohnson

Your Last-Minute Market Moves: Unpacking Today's 'Final Trades'

Why Wall Street is Betting Big on These Rock-Solid Dividend Aristocrats

Another Chapter Unfolds: Jury Finds Johnson & Johnson Liable in Baby Powder Cancer Case

Tylenol and Autism: Navigating New Research on Prenatal Acetaminophen Use

NVIDIA's Current Quandary: Can the AI Kingpin Reignite Its Stock Performance?

Penumbra Shares Skyrocket: Is a Major Takeover Really Brewing?

The Shattered Trust: A Giant's Shadow Over Millions

Major Blow to Johnson & Johnson: Jury Awards $40 Million in Talcum Powder Cancer Case

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

Another Heartbreak in the Alzheimer's Fight: J&J's Posdinemab Stumbles

The AI Showdown: Is Google's Gemini Poised to Shake Up the Tech Giants?

The Great Sector Shuffle: Uncovering Tomorrow's Winners Amidst Market Flux

The Quiet Confidence: Why Searle & Co. Just Doubled Down on Johnson & Johnson

Beyond Just Income: Why Wall Street's Savviest are Eyeing These Three Dividend Powerhouses

The Tylenol Tangle: Texas Challenges a Phantom Autism Link

The Unseen Cost? Texas Takes On Tylenol Makers Over Autism Link Claims

Tylenol in the Crosshairs: Texas Families Seek Answers on Autism Allegations

The Dow's High Flyers: Can Earnings Sustain the Momentum?

The Talc Tempest: Johnson & Johnson Faces Cancer Claims and Billions in Legal Battles

Johnson & Johnson Considers Major Orthopedic Business Split

Carvykti's Q3 Performance: Legend Biotech Navigates Sales Landscape

Johnson & Johnson Soars: Q3 Earnings Crush Expectations, Full-Year Forecast Skyrockets!

Johnson & Johnson's Bold Orthopedics Spin-Off: A New Era of Growth and Value Unveiled

Johnson & Johnson Soars Past Expectations with Stellar Q3 Earnings, Driven by Pharmaceutical and MedTech Growth

Johnson & Johnson Soars: Beating Q3 Expectations and Raising Full-Year Outlook

J&J's Q3 Rollercoaster: Stock Dip, MedTech Hopes, and Tariff Tangles!

The S&P 500's Moment of Truth: Why the 20-Day Moving Average is the Market's Next Big Test

Momentum Mavericks: 5 Powerhouse Stocks Poised for Big Earnings Weeks Ahead

Wall Street Reacts: Top Stock Moves and Analyst Insights Shaping Thursday's Market

The Billions at Stake: Johnson & Johnson's Decisive Move in Talc Litigation

The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

Is Pharma Poised for a Powerful Rebound? Chart Master Sees a Major Breakout Ahead

Navigating the AI Stock Landscape: Smart Bets Beyond the Hype, According to Trivariate

Unleash Your Potential: Johnson & Johnson's 'Dual Control' Empowers IBD Patients in Asia Pacific

Navigating the Storm: 20 Defensive Dividend Stocks to Weather a Government Shutdown

Johnson & Johnson's Unwavering Commitment to Innovation: A Glimpse into the Future of Healthcare

Pharma's Unseen Shift: Citi's Meacham Reveals Deep-Rooted U.S. Investment Promises Already Underway

Kenvue's Rollercoaster: How Tylenol Maker's Shares Defied Trump's Autism Claims

Tylenol's Triumphant Rebound: How Scientific Truth Silenced Unfounded Claims and Propelled J&J's Stock